Screening guidelines for pediatric psoriasis comorbidities
The guidelines are the first to provide recommendations for comorbidity screening in pediatric psoriasis patients.
Psoriasis
Cardiometabolic comorbidity rates high in psoriasis patients
The most common comorbidities found in patients with psoriasis are hyperlipidemia, hypertension, depression, type 2 diabetes mellitus, and obesity.
Biologic treatment for psoriasis shows long-term effectiveness
Researchers sought to analyze long-term and real-world outcome data in patients with moderate-to-severe psoriasis after starting biologic treatment.
First-line biologic treatment for psoriasis influenced by specific factors
Presence of psoriatic arthritis, weight, employment status, baseline disease severity affect the selection of first-line biologic treatment.
High fatigue common in psoriatic arthritis
Nearly 50% of patients with psoriatic arthritis report elevated levels of fatigue.
FDA approves Inflectra biosimilar for rheumatoid arthritis, psoriasis
The biosimilar has also been approved for Crohn’s disease, ulcerative colitis, and ankylosing spondylitis.
Psoriasis severity linked to work productivity, quality of life
Mild, moderate, and severe psoriasis can patients’ quality of life and workplace productivity.
Patients with psoriasis have an increased risk of abdominal aortic aneurysm
Patients with psoriasis are more likely to have an abdominal aortic aneurysm, with the likelihood increasing with more severe psoriasis.
Severe psoriasis, nail pitting possible risks for development of psoriatic arthritis
Researchers found that the annual incidence rate of PsA was 2.7 cases per 100 psoriasis patients.
Current and emerging medications for psoriasis
A number of therapeutic options exist for patients with psoriasis, including phototherapy and systemic and biologic agents.
Next post in Features
